National Security Commission on Emerging Biotechnology Applauds U.S. House Passage of BIOSECURE Act
11 September 2024
FOR IMMEDIATE RELEASE
Washington, DC –
Today, several Commissioners on the National Security Commission for Emerging Biotechnology (NSCEB) applaud the House’s passage of H.R. 8333, the BIOSECURE Act. These Commissioners have previously affirmed their support for the protective measures outlined in the BIOSECURE Act and continue to urge Congress to further promote a robust domestic biotechnology innovation landscape.
“This is an important first step to protect the industry and our critical supply chains from interference by our nation’s adversaries. We can’t stop there, though. Now, Congress should act to enable a flourishing biotechnology sector that keeps us at the leading edge of innovation.” – NSCEB Vice Chair Michelle Rozo
With the BIOSECURE Act progressing through Congress, lawmakers and the biotechnology industry should explore ways to develop a resilient and reliable domestic biotechnology supply chain infrastructure that can provide cost-completive solutions.
The United States is the global leader in biotechnology innovation, but continued leadership is not guaranteed. The Federal government has an important role to play in promoting industry growth and long-term stability. It is also uniquely positioned to help prioritize innovation in emerging biotechnologies so that the United States continues to lead the world in breakthrough development.
“The potential of biotechnology to help meet the challenges of the future is enormous. We must protect, promote, and prioritize U.S. biotechnology so the industry is prepared to deliver.” – NSCEB Commissioner Dawn Meyerriecks
About NSCEB: The National Security Commission on Emerging Biotechnology is a legislative branch advisory entity whose purpose is to advance and secure biotechnology, biomanufacturing, and associated technologies for U.S. national security and to prepare the United States for the age of biotechnology. The Commission submitted an interim report to the President and the Armed Services Committees in December 2023 and will publish a comprehensive report in early 2025, including recommendations for action by Congress and the federal government. The bipartisan Commission is composed of twelve Commissioners with members from both the Senate and the House of Representatives as well as experts from industry, academia, and government. For more information about the Commission, visit https://biotech.senate.gov .
Media inquiries and meeting requests should be directed to the Commission’s Press Secretary, Allison Check, at allison_check@biotech.senate.gov.
